New drug combo targets Hard-to-Treat leukemia
NCT ID NCT05441514
First seen Sep 30, 2025 · Last updated May 25, 2026 · Updated 25 times
Summary
This early-stage trial tested a combination of two targeted drugs, enasidenib and cobimetinib, in 3 adults with a specific genetic form of acute myeloid leukemia (AML) that had returned or not responded to prior treatment. The main goals were to find the safest dose and identify side effects. The approach aims to block cancer growth by targeting two different faulty proteins in the leukemia cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
Conditions
Explore the condition pages connected to this study.